Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

BA-BE Studies: SOP for Batch Rejection and Repeat Analysis – V 2.0

Posted on By

BA-BE Studies: SOP for Batch Rejection and Repeat Analysis – V 2.0

Standard Operating Procedure for Batch Rejection and Repeat Analysis in BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/197/2025
Supersedes SOP/BA-BE/197/2022
Page No. Page 1 of 9
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

This SOP outlines the systematic procedure to identify criteria for rejecting analytical batches and the process to repeat the analysis, ensuring that data quality and regulatory compliance are maintained during bioanalytical evaluations in BA/BE studies.

2. Scope

This SOP applies to all bioanalytical runs performed in the quantification of drug concentrations in biological matrices like plasma, serum, or urine under BA/BE studies conducted

at the bioanalytical laboratory.

3. Responsibilities

  • Analyst: Performs initial batch review and flags issues requiring batch rejection.
  • QA Officer: Reviews justification for rejection and ensures documentation is complete.
  • Bioanalytical Reviewer: Approves repeat analysis plan and verifies data compliance post-repeat.
  • Bioanalytical Head: Authorizes final decision on batch rejection and approves repeat analysis.
See also  BA-BE Studies: SOP for Interim Clinical Monitoring Reports - V 2.0

4. Accountability

The Bioanalytical Head is accountable for maintaining data integrity by ensuring rejected batches are properly documented and repeat analyses are justified and conducted according to applicable guidelines.

5. Procedure

5.1 Criteria for Batch Rejection

  1. An analytical batch shall be rejected if:
    • QC sample failure exceeds the acceptable limits as per ICH M10 (more than 33% of total or 50% at any level).
    • Calibration curve fails to meet accuracy or linearity criteria.
    • System suitability parameters (e.g., peak shape, retention time) are out of range.
    • Chromatographic issues such as interference, co-elution, or carryover.
    • Deviation in run sequence, labeling, or sample position errors.

5.2 Documentation of Batch Rejection

  1. Record rejection details in Annexure-1: Batch Rejection Log including:
    • Run ID
    • Study code
    • Date of analysis
    • Reason for rejection
    • Authorized by
  2. Annotate chromatograms and data files clearly with “REJECTED” watermark and maintain in the archival file.
See also  BA-BE Studies: SOP for Preparing Clinical Investigator’s Brochure (CIB) - V 2.0

5.3 Planning Repeat Analysis

  1. Prepare a Repeat Analysis Request Form (Annexure-2) with:
    • List of samples to be repeated
    • Justification
    • Proposed method and timeline
  2. QA and Bioanalytical Head must jointly approve the repeat analysis plan before initiation.
  3. Repeat analysis must use:
    • Fresh calibration and QC samples
    • Same method and validated parameters

5.4 Conduct of Repeat Analysis

  1. Follow same procedures as in the original batch preparation and processing.
  2. Maintain records in the Repeat Analysis Log (Annexure-3).
  3. Tag repeat runs with a unique batch ID and reference original run ID.

5.5 Review and Reporting

  1. Compare original and repeat results and justify any variation in values exceeding ±20%.
  2. Include repeat run data in the bioanalytical report with annotations and explanation for original run failure.
  3. Ensure that the final reported result is from the repeat batch unless otherwise justified.

6. Abbreviations

  • BA/BE: Bioavailability/Bioequivalence
  • SOP: Standard Operating Procedure
  • QC: Quality Control
  • QA: Quality Assurance
  • ICH: International Council for Harmonisation

7. Documents

  1. Batch Rejection Log – Annexure-1
  2. Repeat Analysis Request Form – Annexure-2
  3. Repeat Analysis Log – Annexure-3
See also  BA-BE Studies: SOP for Analyst Training on LC-MS/MS Operation - V 2.0

8. References

  • ICH M10 Bioanalytical Method Validation Guideline
  • FDA Guidance on Bioanalytical Method Validation (2022)
  • OECD GLP Principles

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Batch Rejection Log

Date Run ID Study Code Reason Approved By
17/04/2025 RUN-058 BE/ABC/2025 QC Failure Sunita Reddy

Annexure-2: Repeat Analysis Request Form

Sample IDs Original Run ID Justification Approval Date Authorized By
SUB005, SUB006 RUN-058 Peak anomaly 17/04/2025 Rajesh Kumar

Annexure-3: Repeat Analysis Log

Date Repeat Run ID Original Run ID Analyst Remarks
18/04/2025 RUN-058R RUN-058 Ajay Verma QC Passed

Revision History:

Revision Date Revision No. Details Reason Approved By
01/01/2022 1.0 Initial SOP New Process Implementation QA Head
17/04/2025 2.0 Included CAPA tracking and reinjection references Audit Compliance QA Head
BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

Post navigation

Previous Post: Biosimilars: SOP for Media Compatibility Assessment – V 2.0
Next Post: Elixir Department: SOP for Use of Vacuum Transfer Systems – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version